EquityNifty Pharma Struggles To Scale New High, Remains Range-Bound Since April: Reasons Behind StagnationBY Rishabh Raj
EquityPharma Stocks Gain Up To 5.50 Per Cent As US Outlines Plan To Lower Drug PricesBY Outlook Money
EquityTrump’s Tariff Pause: Domestic Pharma Stocks Gain Up To 7 Per Cent, Nifty Pharma Surges 3 Per CentBY Outlook Money
EquityMankind, Torrent Dodge Trump's Tariff Torpedo Even As Pharma Index Declines 3 Per Cent In Five Sessions, Know WhyBY Ayush Khar
EquityNifty Pharma Shares Trade In Green After Getting Respite From Trump’s Reciprocal TariffsBY Outlook Money
EquityTrump's 26 Per Cent Tariff On India Triggers Sell-Off In Sensex And Nifty: IT Worst Hit, Pharma Top Sectoral GainerBY Outlook Money
EquityNifty Pharma In Red, Dr Reddy, Lupin, Aurobindo, Sun Pharma Down Up To 3 Per Cent; Here’s WhyBY Outlook Money
NewsKeep Faith On IT, Pharma, Banking Stocks: HDFC AMC’s Prashant Jain Advises InvestorsBY Outlook Money
